Application of antisense conjugates for the treatment of myotonic dystrophy type 1

HIGHLIGHTS

  • who: Jessica Stoodley and collaborators from the Department of Paediatrics, Institute of Developmental and Regenerative Medicine (IDRM), University of Oxford, Roosevelt Dr, Oxford , TY, UK have published the article: Application of Antisense Conjugates for the Treatment of Myotonic Dystrophy Type 1, in the Journal: (JOURNAL)
  • what: Cell-penetrating peptides (CPPs) beand directly to charge-neutral tral ASO chemistries, such ascan PMO PNA,conjugated and this approach has been taken in ASO chemistries, such assplice-switching PMO and PNA,diseases and this approach been takenofinpeptide severalPMOs (P different .
  • future: Advancements in chemical modifications and . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?